ClinicalTrials.gg

Program

Sulfasalazine

Also written as “Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Arthritis, Juvenile · Arthritis, Rheumatoid, led by 2 companies.

Furthest: phase 4, since Feb 11, 20204 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb20 open or runningphase 1since Feb 11, 2020Feb 11, 2020none ahead
Pfizer20 open or runningphase 4since Jan 11, 2007Jan 11, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2007First study: phase 4 study in Arthritis, RheumatoidNew to PfizerPfizer · NCT00422227 · 300 enrolled · Hong Kong, India, Korea, Republic of and more
  2. Mar 11, 2008Phase 4 study in Arthritis, JuvenilePfizer · NCT00637780 · 2 enrolled · United States, Mexico
  3. Feb 11, 2020Bristol-Myers Squibb's first study: phase 1 study in Healthy VolunteerNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT04268394 · 48 enrolled · United Kingdom
  4. Jun 30, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05445440 · 30 enrolled · United States

TargetBeta

“Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05445440Healthy Participants · United States1CompletedBristol-Myers SquibbNov 17, 202230
NCT04268394Healthy Volunteer · United Kingdom1CompletedBristol-Myers SquibbJun 2, 202148
NCT00637780Arthritis, Juvenile · United States, Mexico4TerminatedPfizerJan 20142
NCT00422227Arthritis, Rheumatoid · Hong Kong, India, Korea, Republic of and more4CompletedPfizerMar 2009300

How it is read

Names in the registry

  • “Sulfasalazine”, 6 entries
  • “Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.